2Li J M,Wu D P.Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome:a multicenter study of 112 Chinese patients[J].Int J Hematol,2005,82(1):48.
3Harouseau J L,Wu D P.The use of GM-CSF and G-CSF in the treatment of acute leukemia[J].Leuk Lymphoma,1995,18:405.
4Saito K.Low-dose cytosine arabinoside and aclarubicin in combination with granulocytcolony-stimulating factor for the treatment of relapsed acute myeloid leukemia[J].Rinsho Ketsueki,1996,37(8):651.
5Saito K,Furusawa S.Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia[J].Rinsho Ketsueki,1995,36(3):165.
6Saito K,Nakamura Y.Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor(CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML) and previously anemia with excess blasts in transformation[J].Int J Hematol,2000,71:238.
8Amuguleng B,Hiroshi K.Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells[J].Exp Hematol,1999,27:259.
9Katagiri T,Miyazawa k.Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro[J].Leuk Lymphoma,2000,39:173.
二级参考文献3
1KaranesC,KopeckyKJ,HeadDR ,etal.AphaseⅢcomparisonofhighdoseARA C (HIDAC)versusHIDACplusmitoxantroneinthetreatmentoffirstreplasedorrefractoryacutemyeloidleukemiaSouthwestOncologyGroupStudy[].LeukRes.1999
3Creutzig U,Ritter J,Zimmermann M,et al.Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93[].Journal of Clinical Oncology.2001
8Legrand O ,Perrot JY, Simonin G,et al. Adult biphenotypic acute leukemia:an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein overexpression[J]. Br J Haematol, 1998,100 : 147-155.
9Oaidah TM, A1 Beihany A, Iqbal MA, et al. Cytogenetics, molecular and ultrastructural characteristias of biphenotypic acute leukemia identified by the EGIIJ scoring system[J]. Leukemia,2006,20:620- 626.
